Serum omentin levels: A possible contribution to vascular involvement in patients with systemic sclerosis

The Journal of Dermatology
Shunsuke MiuraTakafumi Kadono

Abstract

Adipokines have been shown to be potentially involved in various pathological processes of systemic sclerosis (SSc), including inflammation, vasculopathy and fibrosis, through their pleiotropic effects. Omentin is a member of the adipokines, and has a protective effect against vascular inflammation and pathological remodeling leading to atherosclerosis as well as a vasodilatory effect. To assess the potential role of omentin in the development of SSc, we determined serum omentin levels by enzyme-linked immunosorbent assay in 66 SSc and 21 control subjects and evaluated their clinical correlation. Serum omentin levels were significantly decreased in diffuse cutaneous SSc patients compared with limited cutaneous SSc patients, while comparable between total SSc patients and healthy controls. In diffuse cutaneous (dc)SSc, patients with a disease duration of 5 years or less had serum omentin levels significantly lower than those with a disease duration of more than 5 years. In total SSc, serum omentin levels were significantly higher in patients with elevated right ventricular systolic pressure than in the others, while serum omentin levels did not correlate with fibrotic and systemic inflammatory parameters. These results suggest t...Continue Reading

References

Dec 1, 1996·Clinical and Experimental Immunology·M B HillP Hughes
Feb 1, 1997·The American Journal of Medicine·K V SalojinP Y Youinou
Oct 29, 1998·Biochemical and Biophysical Research Communications·T KomiyaS Hirohashi
May 5, 1999·Clinical Immunology : the Official Journal of the Clinical Immunology Society·M B KahalehT Otsuka
Jan 3, 2006·Biochimica Et Biophysica Acta·A SchäfflerC Büchler
Mar 15, 2006·American Journal of Physiology. Endocrinology and Metabolism·Rong-Ze YangDa-Wei Gong
Apr 26, 2008·Circulation Research·Charles C Matouk, Philip A Marsden
Jun 12, 2009·Rheumatology·D J AbrahamO Distler
Feb 23, 2010·Biochemical and Biophysical Research Communications·Hideyuki YamawakiYukio Hara
Feb 24, 2010·The Journal of Dermatology·Yoshihide Asano
Feb 5, 2011·Obesity·José Maria Moreno-NavarreteJosé Manuel Fernández-Real
Apr 21, 2011·Journal of the European Academy of Dermatology and Venereology : JEADV·Y MasuiT Kadono
Jul 2, 2011·Obesity·Anna Prats-PuigAbel López-Bermejo
Jul 12, 2011·Trends in Cardiovascular Medicine·Bee K TanHarpal S Randeva
Nov 25, 2011·Journal of the European Academy of Dermatology and Venereology : JEADV·N AozasaS Sato
Jan 4, 2012·Journal of the European Academy of Dermatology and Venereology : JEADV·T ToyamaT Kadono
Jul 21, 2012·Kidney & Blood Pressure Research·Aytekin AlcelikMehmet Yazici
Feb 19, 2013·Journal of Autoimmunity·Yangyang LuoQianjin Lu
Nov 23, 2013·Modern Rheumatology·Takehiro TakahashiShinichi Sato
Apr 15, 2014·American Journal of Physiology. Heart and Circulatory Physiology·Kyosuke KazamaHideyuki Yamawaki

❮ Previous
Next ❯

Citations

Feb 27, 2019·Archives of Dermatological Research·Jakub ŻółkiewiczLidia Rudnicka
Dec 20, 2019·Artificial Cells, Nanomedicine, and Biotechnology·Bin ChaiJun Lu
May 11, 2017·Immunologic Research·Masutaka FurueTakafumi Kadono

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia Cerebrovascular Disease

Basal ganglia cerebrovascular disease is a condition where the blood vessels in the basal ganglia are damaged or malfunction. Discover the latest research on basal ganglia cerebrovascular disease here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.